86 related articles for article (PubMed ID: 15320990)
1. DNA immunization with HIV early genes in HIV type 1-infected patients on highly active antiretroviral therapy.
Hejdeman B; Boström AC; Matsuda R; Calarota S; Lenkei R; Fredriksson EL; Sandström E; Bratt G; Wahren B
AIDS Res Hum Retroviruses; 2004 Aug; 20(8):860-70. PubMed ID: 15320990
[TBL] [Abstract][Full Text] [Related]
2. Immune responses in asymptomatic HIV-1-infected patients after HIV-DNA immunization followed by highly active antiretroviral treatment.
Calarota SA; Leandersson AC; Bratt G; Hinkula J; Klinman DM; Weinhold KJ; Sandström E; Wahren B
J Immunol; 1999 Aug; 163(4):2330-8. PubMed ID: 10438897
[TBL] [Abstract][Full Text] [Related]
3. Amplified antigen-specific immune responses in HIV-1 infected individuals in a double blind DNA immunization and therapy interruption trial.
Gudmundsdotter L; Wahren B; Haller BK; Boberg A; Edbäck U; Bernasconi D; Buttò S; Gaines H; Imami N; Gotch F; Lori F; Lisziewicz J; Sandström E; Hejdeman B
Vaccine; 2011 Jul; 29(33):5558-66. PubMed ID: 21300092
[TBL] [Abstract][Full Text] [Related]
4. Gene combination raises broad human immunodeficiency virus-specific cytotoxicity.
Calarota SA; Kjerrström A; Islam KB; Wahren B
Hum Gene Ther; 2001 Sep; 12(13):1623-37. PubMed ID: 11535166
[TBL] [Abstract][Full Text] [Related]
5. The PEDVAC trial: preliminary data from the first therapeutic DNA vaccination in HIV-infected children.
Palma P; Romiti ML; Li Pira G; Montesano C; Mora N; Aquilani A; Santilli V; Tchidjou HK; Ivaldi F; Giovannelli L; Pontrelli G; Borra G; Blomberg P; Gudmundsdotter L; Bråve A; Montano M; Bernardi S; Manca F; Wahren B; Rossi P
Vaccine; 2011 Sep; 29(39):6810-6. PubMed ID: 21216310
[TBL] [Abstract][Full Text] [Related]
6. Better preserved immune responses after immunization with rgp 160 in HIV-1 infected patients treated with highly active antiretroviral therapy than in untreated patients with similar CD4 levels during at 2 years' follow-up.
Hejdeman B; Leandersson AC; Fredriksson EL; Sandström E; Wahren B; Bratt G
HIV Med; 2003 Apr; 4(2):101-10. PubMed ID: 12702130
[TBL] [Abstract][Full Text] [Related]
7. Indicators of therapeutic effect in FIT-06, a Phase II trial of a DNA vaccine, GTU(®)-Multi-HIVB, in untreated HIV-1 infected subjects.
Vardas E; Stanescu I; Leinonen M; Ellefsen K; Pantaleo G; Valtavaara M; Ustav M; Reijonen K
Vaccine; 2012 Jun; 30(27):4046-54. PubMed ID: 22549090
[TBL] [Abstract][Full Text] [Related]
8. HIV-1 Reservoir Dynamics after Vaccination and Antiretroviral Therapy Interruption Are Associated with Dendritic Cell Vaccine-Induced T Cell Responses.
Andrés C; Plana M; Guardo AC; Alvarez-Fernández C; Climent N; Gallart T; León A; Clotet B; Autran B; Chomont N; Gatell JM; Sánchez-Palomino S; García F
J Virol; 2015 Sep; 89(18):9189-99. PubMed ID: 26109727
[TBL] [Abstract][Full Text] [Related]
9. Influence of a vaccination schedule on viral load rebound and immune responses in successfully treated HIV-infected patients.
Castro P; Plana M; González R; López A; Vilella A; Argelich R; Gallart T; Pumarola T; Bayas JM; Gatell JM; García F
AIDS Res Hum Retroviruses; 2009 Dec; 25(12):1249-59. PubMed ID: 19943787
[TBL] [Abstract][Full Text] [Related]
10. Immunological responses and long-term treatment interruption after human immunodeficiency virus type 1 (HIV-1) lipopeptide immunization of HIV-1-infected patients: the LIPTHERA study.
Pialoux G; Quercia RP; Gahery H; Daniel N; Slama L; Girard PM; Bonnard P; Rozenbaum W; Schneider V; Salmon D; Guillet JG
Clin Vaccine Immunol; 2008 Mar; 15(3):562-8. PubMed ID: 18184824
[TBL] [Abstract][Full Text] [Related]
11. Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients.
Calarota S; Bratt G; Nordlund S; Hinkula J; Leandersson AC; Sandström E; Wahren B
Lancet; 1998 May; 351(9112):1320-5. PubMed ID: 9643795
[TBL] [Abstract][Full Text] [Related]
12. mRNA-based dendritic cell vaccination induces potent antiviral T-cell responses in HIV-1-infected patients.
Van Gulck E; Vlieghe E; Vekemans M; Van Tendeloo VF; Van De Velde A; Smits E; Anguille S; Cools N; Goossens H; Mertens L; De Haes W; Wong J; Florence E; Vanham G; Berneman ZN
AIDS; 2012 Feb; 26(4):F1-12. PubMed ID: 22156965
[TBL] [Abstract][Full Text] [Related]
13. Clinical phase 1 testing of the safety and immunogenicity of an epitope-based DNA vaccine in human immunodeficiency virus type 1-infected subjects receiving highly active antiretroviral therapy.
Wilson CC; Newman MJ; Livingston BD; MaWhinney S; Forster JE; Scott J; Schooley RT; Benson CA
Clin Vaccine Immunol; 2008 Jun; 15(6):986-94. PubMed ID: 18400976
[TBL] [Abstract][Full Text] [Related]
14. New CD4+ and CD8+ T cell responses induced in chronically HIV type-1-infected patients after immunizations with an HIV type 1 lipopeptide vaccine.
Gahery H; Daniel N; Charmeteau B; Ourth L; Jackson A; Andrieu M; Choppin J; Salmon D; Pialoux G; Guillet JG
AIDS Res Hum Retroviruses; 2006 Jul; 22(7):684-94. PubMed ID: 16831093
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic immunization of highly active antiretroviral therapy-treated HIV-1-infected patients: safety and immunogenicity of an HIV-1 gag/poly-epitope DNA vaccine.
Dorrell L; Yang H; Iversen AK; Conlon C; Suttill A; Lancaster M; Dong T; Cebere I; Edwards A; Rowland-Jones S; Hanke T; McMichael AJ
AIDS; 2005 Aug; 19(12):1321-3. PubMed ID: 16052088
[TBL] [Abstract][Full Text] [Related]
16. Effect of therapeutic immunization with HIV type 1 recombinant glycoprotein 160 ImmunoAG vaccine in HIV-infected individuals with CD4+ T cell counts of >or=500 and 200-400/mm3 (AIDS Clinical Trials Group Study 246/946).
Kundu-Raychaudhuri S; Sevin A; Kilgo P; Nokta M; Pollard RB; Merigan TC
AIDS Res Hum Retroviruses; 2001 Oct; 17(15):1371-8. PubMed ID: 11679149
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic vaccination of HIV-1-infected patients on HAART with a recombinant HIV-1 nef-expressing MVA: safety, immunogenicity and influence on viral load during treatment interruption.
Harrer E; Bäuerle M; Ferstl B; Chaplin P; Petzold B; Mateo L; Handley A; Tzatzaris M; Vollmar J; Bergmann S; Rittmaier M; Eismann K; Müller S; Kalden JR; Spriewald B; Willbold D; Harrer T
Antivir Ther; 2005; 10(2):285-300. PubMed ID: 15865223
[TBL] [Abstract][Full Text] [Related]
18. Immune responses but no protection against SHIV by gene-gun delivery of HIV-1 DNA followed by recombinant subunit protein boosts.
Putkonen P; Quesada-Rolander M; Leandersson AC; Schwartz S; Thorstensson R; Okuda K; Wahren B; Hinkula J
Virology; 1998 Oct; 250(2):293-301. PubMed ID: 9792840
[TBL] [Abstract][Full Text] [Related]
19. MVA-nef induces HIV-1-specific polyfunctional and proliferative T-cell responses revealed by the combination of short- and long-term immune assays.
Kutscher S; Allgayer S; Dembek CJ; Bogner JR; Protzer U; Goebel FD; Erfle V; Cosma A
Gene Ther; 2010 Nov; 17(11):1372-83. PubMed ID: 20535218
[TBL] [Abstract][Full Text] [Related]
20. Long-term persistence of vaccination and HAART to human immunodeficiency virus (HIV).
Boström AC; Hejdeman B; Matsuda R; Fredriksson M; Fredriksson EL; Bratt G; Sandström E; Wahren B
Vaccine; 2004 Apr; 22(13-14):1683-91. PubMed ID: 15068851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
